Monoclonal antibodies against ANGPTL4
View Patent ↗Monoclonal antibodies that specifically bind to ANGPTL4 are provided. Monoclonal antibodies that neutralize at least one activity of ANGPTL4 are provided. Methods of treating a disorder of lipid metabolism using neutralizing monoclonal antibodies are provided.
1. A monoclonal antibody comprising a heavy chain and a light chain, wherein the heavy chain comprises a first CDR1, a first CDR2, and a first CDR3, wherein the first CDR1 comprises an amino acid sequence as set forth in SEQ ID NO: 21, the first CDR2 comprises an amino acid sequence as set forth in SEQ ID NO: 22, and the first CDR3 comprises an amino acid sequence as set forth in SEQ ID NO: 23, and the light chain comprises a second CDR1, a second CDR2, and a second CDR3, wherein the second CDR1 comprises an amino acid sequence as set forth in SEQ ID NO: 30, the second CDR2 comprises an amino acid sequence as set forth in SEQ ID NO: 31, and the second CDR3 comprises a sequence as set forth in SEQ ID NO: 32.
2. The antibody of claim 1 , wherein the antibody is a mouse antibody.
3. The antibody of claim 1 , wherein the antibody is a humanized antibody.
4. The antibody of claim 1 , wherein the antibody is a fragment selected from an scFv, a Fab, a Fab′, and a (Fab′) 2 .
5. The antibody of claim 1 , wherein the heavy chain comprises an amino acid sequence as set forth in SEQ ID NO: 12 and the light chain comprises an amino acid sequence as set forth in SEQ ID NO: 16.
6. A pharmaceutical composition comprising the antibody of claim 1 and at least one pharmaceutically acceptable ingredient selected from a diluent, a carrier, a solubilizer, an emulsifier, a preservative, and an adjuvant.
7. A monoclonal antibody comprising a heavy chain and a light chain, wherein the heavy chain comprises a first CDR1, a first CDR2, and a first CDR3, wherein the first CDR1 comprises an amino acid sequence as set forth in SEQ ID NO: 24, the first CDR2 comprises an amino acid sequence as set forth in SEQ ID NO: 25, and the first CDR3 comprises an amino acid sequence as set forth in SEQ ID NO: 26, and the light chain comprises a second CDR1, a second CDR2, and a second CDR3, wherein the second CDR1 comprises an amino acid sequence as set forth in SEQ ID NO: 33, the second CDR2 comprises an amino acid sequence as set forth in SEQ ID NO: 34, and the second CDR3 comprises an amino acid sequence as set forth in SEQ ID NO: 35.
8. The antibody of claim 7 , wherein the heavy chain comprises an amino acid sequence as set forth in SEQ ID NO: 13 and the light chain comprises an amino acid sequence as set forth in SEQ ID NO: 17.
9. The antibody of claim 7 , wherein the antibody is a mouse antibody.
10. The antibody of claim 7 , wherein the antibody is a humanized antibody.
11. The antibody of claim 7 , wherein the antibody is a fragment selected from an scFv, a Fab, a Fab′, and a (Fab′) 2 .
12. A pharmaceutical composition comprising the antibody of claim 7 and at least one pharmaceutically acceptable ingredient selected from a diluent, a carrier, a solubilizer, an emulsifier, a preservative, and an adjuvant.
13. A monoclonal antibody comprising a heavy chain and a light chain, wherein the heavy chain comprises a first CDR1, a first CDR2, and a first CDR3, wherein the first CDR1 comprises an amino acid sequence as set forth in SEQ ID NO: 27, the first CDR2 comprises an amino acid sequence as set forth in SEQ ID NO: 28, and the first CDR3 comprises an amino acid sequence as set forth in SEQ ID NO: 29, and the light chain comprises a second CDR1, a second CDR2, and a second CDR3, wherein the second CDR1 comprises an amino acid sequence as set forth in SEQ ID NO: 36, the second CDR2 comprises an amino acid sequence as set forth in SEQ ID NO: 37, and the second CDR3 comprises an amino acid sequence as set forth in SEQ ID NO: 38.
14. The antibody of claim 13 , wherein the heavy chain comprises an amino acid sequence as set forth in SEQ ID NO: 14 and the light chain comprises an amino acid sequence as set forth in SEQ ID NO: 18.
15. The antibody of claim 13 , wherein the antibody is a mouse antibody.
16. The antibody of claim 13 , wherein the antibody is a humanized antibody.
17. The antibody of claim 13 , wherein the antibody is a fragment selected from an scFv, a Fab, a Fab′, and a (Fab′) 2 .
18. A pharmaceutical composition comprising the antibody of claim 13 and at least one pharmaceutically acceptable ingredient selected from a diluent, a carrier, a solubilizer, an emulsifier, a preservative, and an adjuvant.